Clinical Trial Update January 2026 - Summary - MDSpire

Clinical Trial Update January 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

  • January 1, 2026

  • 38 min

Share

Objective:

To provide an overview of active clinical trials focused on age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and uveitis.

Approach:
    Key Findings:
    • Multiple studies are assessing new treatments for geographic atrophy associated with AMD.
    • Various study designs include randomized, double-blind, and multicenter approaches.
    • Patient numbers range from small (15) to larger cohorts (311) across different trials.
    Interpretation:

    The ongoing clinical trials reflect a robust effort to explore new therapeutic options for AMD and related conditions, indicating a growing interest in innovative treatments.

    Limitations:
    • Limited information on outcomes and results as many studies are still ongoing.
    • Variability in study designs and patient populations may affect generalizability.
    Conclusion:

    The landscape of clinical trials for AMD is expanding, with numerous studies aimed at improving patient outcomes through novel therapies.

    Sources:

Original Source(s)

Clinical Trial Update January 2026

  • January 1, 2026

Related Content

Regulatory T cell dysfunction and exhaustion in uveitis: immunometabolic mechanisms, microenvironmental drivers, and emerging therapeutic strategies

Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models